Abstract
Depression and ischemic heart disease (IHD) are the two most prevalent health problems afflicting patients not only in the United States but worldwide (1). The lifetime prevalence of major depressive disorder in the general population of the United States has been found to be 16.2% (2). The prevalence of depression in medically ill patients is much higher, ranging 20–50%. Depression is a major contributor to work place absenteeism, diminished or lost productivity, and increased use of health services (3). It is also known to increase disability, morbidity, and mortality among the medically ill.
Keywords
- Depressive Symptom
- Heart Rate Variability
- Cognitive Behavior Therapy
- Ischemic Heart Disease
- Major Depressive Disorder
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Murray CJ, Lopez AD, eds. The Global Burden of Disease. Cambridge: Harvard University Press; 1996.
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105.
US Department of Health and Human Services, Mental Health: A Report of the Surgeon General. Rockville: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health; 1999.
Unutzer J, Katon W, Williams JW Jr, et al. Improving primary care for depression in late life: the design of a multicenter randomized trial. Med Care. 2001;39:785–99.
Kurzthaler I, Hotter A, Miller C, et al. Risk profile of SSRIs in elderly depressive patients with co-morbid physical illness. Pharmacopsychiatry. 2001;34:114–8.
Krishnan KR, Doraiswamy PM, Clary CM. Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:347–61.
Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317–29.
Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta- analysis. Diabetes Care. 2001;24:1069–78.
Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000;23:934–42.
de Groot M, Anderson R, Freedland KE, et al. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619–30.
Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care. 2003;26:2822–8.
Egede LE. Diabetes, major depression, and functional disability among US adults. Diabetes Care. 2004;27:421–8
Egede LE. Effects of depression on work loss and disability bed days in individuals with diabetes. Diabetes Care. 2004;27:1751–3.
Goldney RD, Phillips PJ, Fisher LJ, et al. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004;27:1066–70.
Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;160:3278–85.
Lin EH, Katon W, Von Korff M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27:2154–60.
Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care. 2002;25:464–70.
Egede LE, Zheng D. Modifiable cardiovascular risk factors in adults with diabetes: prevalence and missed opportunities for physician counseling. Arch Intern Med. 2002;162:427–33.
Nelson KM, Reiber G, Boyko EJ. Diet and exercise among adults with type 2 diabetes: findings from the third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2002;25:1722–8.
Harris MI. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:979–82.
McKellar JD, Humphreys K, Piette JD. Depression increases diabetes symptoms by complicating patients’ self-care adherence. Diabetes Educ. 2004;30:485–92.
Zhang X, Norris SL, Gregg EW, et al. Depressive symptoms and mortality among persons with and without diabetes. Am J Epidemiol. 2005;161:652–60.
Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care. 2005;28:1339–45.
Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care. 2005;28:2668–72.
Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 2001;13:31–41.
Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry. 2004;61:1042–9.
Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;129:613– 21.
Lustman PJ, Freedland KE, Griffith LS, et al. Predicting response to cognitive behavior therapy of depression in type 2 diabetes. Gen Hosp Psychiatry. 1998;20:302–6.
Baker RA, Andrew MJ, Schrader G, et al. Preoperative depression and mortality in coronary artery bypass surgery: preliminary findings. ANZ J Surg. 2001;71:139–42.
Roose SP, Spatz E. Treating depression in patients with ischaemic heart disease. Which agents are best to use and to avoid? Drug Safety. 1999;20:459–65.
Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–12.
Cardiac Arrhythmia Suppression Trial (CAST) II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227–33.
Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279:287–91.
Nelson JC, Kennedy JS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry. 1999;156:1024–8.
Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 1998;155:660–65.
Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62:783–9.
Glassman AH, O’Connor CM, Califf RM, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–9.
Lesperence F, Frasure-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Candaian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA. 2007;297:367–79.
Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20:137–40.
Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine – preliminary findings. Arch Gen Psychiatry. 2000;57:875–82.
Serebruany VL, Glassman AH, Malinin AI, et al. Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003;108:939–44.
Yeragani VK, Pesce V, Jayaraman A, et al. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry. 2002;52:418–29.
Yeragani VK, Roose S, Mallavarapu M, et al. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology. 2002;46:125–35.
Rechlin T. The effects of psychopharmacological therapy on heart rate variation. Nervenarzt. 1995;66:678–85.
Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894–8.
Berkman LF, Blumenthal J, Burg M, et al. Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289:3106–16.
Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS, ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62:792–8.
Van den Brink RHS, Van Melle JP, Honig A, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the myocardial infarction and depression-intervention trial (MIND-IT). Am Heart J. 2002;144:219–25.
De Jonge P, Hong A, Schene AH, et al. Effects of antidepressive therapy for the treatment of depression following myocardial infarction: results from the Myocardial Infarction and Depression Intervention Trial (MIND_IT). Psychosom Med. 2006;68:A-7.
Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001;43:453–62.
Frasure-Smith N, Lesperance F, Prince RH, et al. Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. Lancet. 1997;350:473–9.
Enrichd Investigators. Enhancing Recovery in Coronary Heart Disease (ENRICHD Investigators) study intervention: rationale and design. Psychosom Med. 2001;63:747–55.
Franc¸ois Lespe´rance, Nancy Frasure-Smith, Diana Koszycki, Marc-Andre´ Laliberte´, Louis T. van Zyl, Brian Baker, John Robert Swenson, Kayhan Ghatavi, Beth L. Abramson, Paul Dorian, Marie-Claude Guertin, for the CREATE Investigators. Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary Artery Disease__The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial. JAMA. 2007;297:367–79.
Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry. 2003;54:376–87.
Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after poststroke depression: a double-blind treatment trial. Stroke. 2000;31:1482–6.
Sturm JW, Donnan GA, Dewey HM, et al. Determinants of handicap after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2004;35:715–20.
House A, Knapp P, Bamford J, Vail A. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke. 2001;32:696–701.
Chan KL, Campayo A, Moser DJ, Arndt S, Robinson RG. Aggressive behavior in patients with stroke: association with psychopathology and results of antidepressant treatment on aggression. Arch Phys Med Rehabil. 2006;87:793–8.
Dam M, Tonin P, DeBoni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211–4.
Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351–9.
Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, Malaguarnera M. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology. 2004;173:73–8.
Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: results from a randomized placebo-controlled trial. J Clin Psychiatry. 2006;67:1104–9.
Niedermaier N, Bohrer E, Schulte K, Schlattmann P, Heuser I. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry. 2004;65:1619–23.
Muller U, Murai T, Bauer-Wittmund T, et al. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj. 1999;13:805–11.
Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet. 1993;342:837–9.
Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke. 2006;37:156–61.
Lyketsos CG, Sheppard JM, Steele CD, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer’s disease: initial results from the Depression in Alzheimer’s Disease study. Am J Psychiatry. 2000;157:1686–89.
Vida S, DesRosiers P, Carrier L, et al. Prevalence of depression in Alzheimer’s disease and validity or research diagnostic criteria. J Geriatr Psychiatry Neurol 1994;7:238–44.
Loreck DJ, Folstein MF. Depression in Alzheimer disease. In: Starkstein SE, Robinson RG editors. Depression in neurologic disease. The John Hopkins series in pyschiatry and neuroscience. Baltimore: John Hopkins University Press; 1993:50–62.
Bains J, Birks JS, Dening TD. Cochrane Dementia and Cognitive Improvement Group Antidepressants for treating depression in dementia Date of Most Recent Update: This version first published online: October 21. 2002; and Last assessed as up-to-date: April 27. 2005. http://www2.cochrane.org/reviews/en/ab003944.html
Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer’s disease patients with and without depression. Am J Psychiatry. 1989;146:45–9.
Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics. 1997;38:246–52.
Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13(2):100–8.
Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer’s disease. A practical update for the clinician. Dement Geriatr Cogn Disord. 2004;17:55–64.
Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86:138–45.
Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–46.
Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer’s disease. Int Psychogeriatr. 2001;13:233–40.
Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894–901.
Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord. 2002;17:60–7.
Dell’Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001;24:221–7.
Menza M, Marin H, Kaufman K, et al. Citalopram treatment of depression in Parkinson’s disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci. 2004;16:315–9.
Strong RR. Imipramine in treatment of parkinsonism: a double blind placebo study. Br Med J. 1965;2:33–4.
Laitinen L. Desipramine in treatment of Parkinson’s disease. Acta Neurol Scand. 1969;45:109–13.
Anderson J, Aabro E, Gulmann N. Anti-depressive treatment in Parkinson’s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with l-dopa. Acta Neurol Scan. 1980;62:210–9.
Goetz CG, Tanner CM, Klawans HL. Buproprion in Parkinson’s disease. Neurology. 1984;34:1092–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jiang, W., Krishnan, K.R.R. (2011). Treatment of Depression in the Medically Ill. In: Ciraulo, D., Shader, R. (eds) Pharmacotherapy of Depression. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-435-7_11
Download citation
DOI: https://doi.org/10.1007/978-1-60327-435-7_11
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-434-0
Online ISBN: 978-1-60327-435-7
eBook Packages: MedicineMedicine (R0)